Expert Ratings for Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target among 20 analysts is $252.65, with a high of $405.00 and a low of $170.00. This target has increased by 1.47% from the previous target of $249.00. Analysts rate stocks based on research and provide guidance which investors should use with caution, as analysts are also human and can only offer opinions.

November 15, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has received predominantly bullish ratings from analysts, with an updated average price target of $252.65, reflecting a 1.47% increase from the previous target.
The positive analyst ratings and the increase in the average price target suggest a favorable outlook for ALNY in the short term. Analyst sentiment can influence investor perception and potentially drive stock prices up. However, the actual impact may vary depending on market conditions and broader economic factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100